Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.

Hardik ChandasanaMita ThaparSiobhan HayesMark BakerDiana M GibbAnna TurkovaDeborah FordTheodore RuelAndrew WizniaLee FairlieMutsa Bwakura-DangarembiziHilda MujuruCarmelita AlveroMona FarhadRohan HazraEllen TownleyAnn BuchananPauline BollenHylke WaalewijnAngela ColbersDavid BurgerEdward P AcostaRajendra Singhnull null

Published in: Clinical pharmacokinetics (2023)

The dolutegravir dosing in children ≥ 4 weeks of age on an age/weight-band basis provides comparable exposures to those historically observed in adults. Observed pharmacokinetic variability was higher in this pediatric population and no additional safety concerns were observed. These results support the weight-banded dosing of dolutegravir in pediatric participants currently recommended by the World Health Organization.

Keyphrases

antiretroviral therapy
hiv infected
hiv infected patients
human immunodeficiency virus
body mass index
weight loss
physical activity
weight gain
young adults
air pollution
body weight